Pulmonology

The FDA agreed to remove a boxed warning from inhalant combinations of corticosteroid and long-acting beta-agonist following research from a collaboration of pharmaceutical manufacturers.

Companion studies of dupilumab find it safe and efficacious, as well as glucocorticoid-sparing in patients with moderate-to-severe asthma.

Targeting metabolism with therapies such as metformin has shown in clinical settings to affect aging itself. In IPF, it could influence the rate of aging as well.

Combined analysis of 2 prospective studies showed that marijuana use was associated with an increased risk for cough and sputum production.

The LIBERATE study revealed 47.7% of those treated with the Zephyr Endobronchial Valve experienced at least a ≥15% improvement on pulmonary function scores, compared with 16.8% of the control group.

The FRESCA Medical, Inc system is designed to operate with less airflow, alleviating some of the complaints that arise with traditional CPAP systems for patients with obstructive sleep apnea.

Researchers noted that a reduction in the frequency of medication regimen has been proven to also aid treatment adherence.

Half of patients admitted to an emergency department for uncontrolled asthma had unknowingly emptied their bronchodilator inhaler, according to a recent study.

The fixed-dose combination therapy from Valeant Pharmaceuticals International is vying to become the first and only approved topical lotion for the condition.

Though patients had a clinically meaningful increase in pre-bronchodilator FEV1, they did not evidence a significantly improved annualized asthma exacerbation rates compared with placebo.

The specifics of the "minor deficiencies" cited by the FDA will be relayed on June 27, 2018, upon the official issuance of the CRL.

The CDC reports that of the 2 million people who get an infection from antibiotic-resistant bacteria each year, about 23,000 die.

Children with autism are nearly twice as likely to have any allergic condition than those without autism, researchers found.

Between 60-80% of pediatric asthma exacerbations are triggered by respiratory pathogens. For most children, the common cold is the culprit.

The rare condition affects 30,000-40,000 US patients annually. Rituximab becomes its first indicated biologic treatment.

A trial of 2 different vitamin D supplementation methods found that one of them is capable of reducing recurrent wheezing in preterm infants.

The fluticasone propionate nasal spray is indicated for treatment of seasonal and perennial allergic rhinitis, as well as the management of sinus pain and pressure associated with pediatric rhinitis.